SYRE · Spyre Therapeutics Inc
United States · RS rating 88 · As of 2026-11-03
| Price | 99.27 USD |
|---|---|
| 1-day change | +3.9% |
| RS rating (overall / 1M / 3M / 12M) | 88 / 76 / 56 / 98 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 45 / 54 / 35 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -280.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +8.9% |
| Market cap (USD) | $6.0B |